@article{b87846a56be847c8a5599af551d6b0df,
title = "Monoclonal Antibody Use for Coronavirus Disease 2019 in Pediatric Patients: A Multicenter Retrospective Study",
abstract = "Monoclonal antibodies for COVID-19 are authorized in high-risk patients aged ≥12 years, but evidence in pediatric patients is limited. In our cohort of 142 patients treated at seven pediatric hospitals between 12/1/20 and 7/31/21, 9% developed adverse events, 6% were admitted for COVID-19 within 30 days, and none received ventilatory support or died.",
keywords = "COVID-19, SARS-CoV-2, bamlanivimab and etesevimab, casirivimab and imdevimab, monoclonal antibodies, pediatric",
author = "Gilad Sherman and Lamb, {Gabriella S.} and Sharma, {Tanvi S.} and Lloyd, {Elizabeth C.} and Jerod Nagel and Dandam, {Nada N.} and Oliveira, {Carlos R.} and Sheikha, {Hassan S.} and Anosike, {Brenda I.} and Philip Lee and Vora, {Surabhi B.} and Karisma Patel and Sue, {Paul K.} and Beenish Rubbab and Yarbrough, {April M.} and Lakshmi Ganapathi and Nakamura, {Mari M.}",
note = "Publisher Copyright: {\textcopyright} The Author(s) 2023. Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society. All rights reserved.",
year = "2023",
month = mar,
day = "1",
doi = "10.1093/jpids/piac124",
language = "English (US)",
volume = "12",
pages = "152--155",
journal = "Journal of the Pediatric Infectious Diseases Society",
issn = "2048-7193",
publisher = "Oxford University Press",
number = "3",
}